DOXIL® in combination with bortezomib is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. It is an intravenous (IV) prescription medication prescribed by your doctor. It is a type of chemotherapy drug known as an anthracycline.
Doxil is also known as doxorubicin HCl liposome injection or pegylated liposomal doxorubicin (PLD). It is distributed by Janssen Products, LP in the United States. Doxil is also approved for the treatment of patients with ovarian cancer and in patients with AIDS-related Kaposi’s sarcoma.